搜尋
AIM ImmunoTech Inc
AIM添加自選
0.279USD
-0.017-5.84%
收盤 06/30, 16:00（美東）報價延遲15分鐘
2.29M總市值
虧損本益比TTM
關於 AIM ImmunoTech Inc 公司
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc簡介
公司代碼AIM
公司名稱AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
員工數量21
證券類型Ordinary Share
年結日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編32801
電話13524487797
網址https://aimimmuno.com/
公司代碼AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)
AIM ImmunoTech Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
常見問題
AIM ImmunoTech Inc的前五大股東是誰？
AIM ImmunoTech Inc的前五大股東如下：Mr. Thomas K. Equels, Esq., J.D.
有多少機構持有AIM ImmunoTech Inc(AIM)的股份？
截至2026Q1，共有57家機構持有AIM ImmunoTech Inc的股份，合計持有的股份價值約為105.74K，占公司總股份的1.30% 。與2025Q4相比，機構持股有所增加，增幅為-74291.00。
